Slide 1: Fiscal First Quarter Ended March 31, 2022 Earnings Presentation
Fiscal First Quarter Ended March 31, 2022 Earnings Presentation May 4, 2022
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hop
Slide 3: Key Messages
Key Messages Government support and high natural gas prices are favorable trends supporting nuclear power and have an improved medium and long-term outlook Order intake strong in the first quarter, underpinning health of underlying market dynamics Rising military and defense budgets are potential op
Slide 4: Fiscal First Quarter Summary
Fiscal First Quarter Ended March 31, 2022 Summary Very healthy core order intake up ~19% compared to Q1 2021 Adjusted Revenue Performance supported by strong demand patterns across the business1 3-months ended Mar. 31, 2022 vs. Mar. 31, 2021 $ millions -4.3% 1Q21 1Q22 Adjusted Revenue of $163.2M and
Slide 5: Mirion | Fiscal First Quarter
Mirion | Fiscal First Quarter Ended March 31, 2022 Adjusted Revenue Adjusted EBITDA and Margin Adjusted Gross Profit Margin Adjusted EPS $ millions | % percentage $ millions | % percentage % percentage | basis points $ millions % Q121 vs. Q122 Public company costs of Organic -4.2% ~$3M in Q1 2022 Ac
Slide 6: Medical | Fiscal First Quarter
Medical | Fiscal First Quarter Ended March 31, 2022 Adjusted Revenue Adjusted EBITDA and Margin MEDICAL SEGMENT $ millions | % percentage $ millions | % percentage Nuclear Medicine % Q121 vs. Q122 Radiotherapy Organic +0.7% Medical Imaging Supply chain negatively impacting adjusted organic +6.3% Occ
Slide 7: Industrial | Fiscal First Quarter
Industrial | Fiscal First Quarter Ended March 31, 2022 Adjusted Revenue Adjusted EBITDA and Margin INDUSTRIAL SEGMENT $ millions | % percentage $ millions | % percentage Nuclear Power % Q121 vs. Q122 Labs & Research Organic -6.6% Supply chain and Diversified Industrial Acquisition n.a. Russia/Ukrain
Slide 8: Leverage, Liquidity and Adjusted Free Cash Flow
Leverage, Liquidity and Adjusted Free Cash Flow As of March 31, 2022 Leverage Liquidity and Adjusted Free Cash Flow • Cash on hand as of March 31, 2022 of $84M • Total liquidity available of $166M incl. undrawn revolver of $82M • Revolving facility includes springing first lien net leverage • Higher
Slide 9: Updated Guidance for the 12 Months Ending December 31, 2022
Updated Guidance for the 12 Months Ending December 31, 2022 Revised Guidance to Account for Russia/Ukraine and Supply Chain Impacts Category1 May 4, 2022 February 23, 2022 What we are seeing and expectations Reported Adj. Revenue Growth 3.5% to 5.5% 5.5% to 7.5% • Update reflects removal of all rema
Slide 10: Mirion First Quarter 2022 Key Takeaways
Mirion First Quarter 2022 Key Takeaways Challenging operating environment in the first quarter from continuing supply chain issues and impacts from the Russia/Ukraine conflict Market conditions trending in a positive direction, supported by orders performance Updated 2022 guidance reflects the remov
Slide 11: Appendix
Appendix &
Slide 12: Nine Quarter Segment Reconciliation - Medical
Nine Quarter Segment Reconciliation Medical Combined (non- Successor GAAP) Predecessor ($ in millions) Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Q1 2020 Revenue $ 60.1 $ 57.5 $ 52.0 $ 52.1 $ 51.5 $ 31.7 $ 20.4 $ 18.1 $ 15.1 Revenue reduction from purchase accounting 3.1 3.7 3.7
Slide 13: Nine Quarter Segment Reconciliation - Industrial
Nine Quarter Segment Reconciliation Industrial Combined (non- Successor GAAP) Predecessor ($ in millions) Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Q1 2020 Revenue $ 103.1 $ 120.3 $ 92.3 $ 127.9 $ 114.7 $ 119.0 $ 94.2 $ 123.0 $ 94.7 Revenue reduction from purchase accounting -
Slide 14: Nine Quarter Segment Reconciliation - Corporate & Other
Nine Quarter Segment Reconciliation Corporate & Other Combined (non- Successor GAAP) Predecessor ($ in millions) Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Q1 2020 Revenue $ - $ - $ - $ - $ - $ - $ - $ - $ - Revenue reduction from purchase accounting - - - - - - - - - Adjusted R
Slide 15: Nine Quarter Segment Reconciliation - Consolidated
Nine Quarter Segment Reconciliation Consolidated Combined (non- Successor GAAP) Predecessor ($ in millions) Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Q1 2020 Revenue $ 163.2 $ 177.8 $ 144.3 $ 180.0 $ 166.2 $ 150.8 $ 114.6 $ 141.2 $ 109.8 Revenue reduction from purchase accounti
Slide 16: Non-GAAP Reconciliations
Non-GAAP Reconciliations Consolidated – Income (loss) from Operations, Adjusted Gross Profit & Adjusted EBITDA Three Months Ended Three Months Ended March 31, 2022 March 31, 2021 ($ in millions) (Successor) (Predecessor) Net income (loss) before minority interest $ (19.0) $ (40.7) Interest expense,
Slide 17: Non-GAAP Reconciliations
Non-GAAP Reconciliations Reconciliation of Adjusted Earnings per Share Three Months Ended March 31, 2022 ($ in millions) (Successor) Net loss attributable to Mirion Technologies, Inc. (Successor) / Mirion Technologies (TopCo), Ltd. (Predecessor) stockholders $ (17.7) Loss attributable to noncontroll
Slide 18: Share Count Details
Share Count Details As of March 31, 20221 Outstanding Fully Diluted Share Description Securities (Illustrative)2,3,4 Notes Shares of Class A Common Stock – Public 180,773,392 180,773,392 Outstanding shares as of close of trading on the New York Stock Exchange (NYSE) March 31, 2022 Shares for EPS C
Slide 19: Footnotes to Share Count and Adjusted Metrics
Footnotes to Share Count and Adjusted Metrics Share Count Consists of 180,773,392 shares of Class A common stock and 8,560,540 shares of Class B common stock outstanding as of March 31, 2022. Excludes (1) 18,750,000 founder shares which are shares of Class A common stock subject to vesting in three
Slide 20: Mirion
m MIRION TECHNOLOGIES MIR LISTED NYSE